Anisocoria secondary to antiperspirant wipes in a pediatric population: a case series.

Abstract

Acute-onset anisocoria or mydriasis in children carries a broad differential diagnosis and includes both benign and life-threatening causes, ranging from systemic or topical drug use to peripheral or central nervous system disease. The topical anticholinergic agent glycopyrronium (approved by the Food and Drug Administration in June 2018) is used to treat hyperhidrosis. We present the first case series of pediatric patients presenting with acute mydriasis due to exposure to glycopyrronium wipes. Six cases (ages 12-16) were identified: 3 presented emergently and 3 to a primary care physician. Additional symptoms included blurry vision (4/6) and unilateral headache (1/6). In 3 cases, use of glycopyrronium wipes was not elicited initially, neuroimaging was obtained, and ophthalmology (2/3) or neurology (1/3) was consulted. One patient remained undiagnosed and presented emergently again 2 months later. In all patients, symptoms resolved without further treatment.

• Authors: Joseph D Pecha, Kimberly G Yen, Alexis Moisiuc, Adam Cantor
• Journal: Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus (J AAPOS) Vol. 26 Issue 1 Pg. 42-43 (02 2022) ISSN: 1528-3933 [Electronic] United States
• PMID: 34798293 (Publication Type: Journal Article)
• Copyright: Copyright © 2021 American Association for Pediatric Ophthalmology and Strabismus. Published by Elsevier Inc. All rights reserved.

Chemical References

• Antiperspirants
• Glycopyrrolate

Topics

• Adolescent
• Anisocoria (chemically induced, diagnosis)
• Antiperspirants (therapeutic use)
• Child
• Glycopyrrolate
• Humans
• Hyperhidrosis (chemically induced, drug therapy)
• Mydriasis (chemically induced, diagnosis)